These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19969320)

  • 1. Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.
    Schaap-Nutt A; D'Angelo C; Scull MA; Amaro-Carambot E; Nishio M; Pickles RJ; Collins PL; Murphy BR; Schmidt AC
    Virology; 2010 Feb; 397(2):285-98. PubMed ID: 19969320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.
    Schaap-Nutt A; D'Angelo C; Amaro-Carambot E; Nolan SM; Davis S; Wise SM; Higgins C; Bradley K; Kim O; Mayor R; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC
    Virology; 2010 Oct; 406(1):65-79. PubMed ID: 20667570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.
    Schaap-Nutt A; Scull MA; Schmidt AC; Murphy BR; Pickles RJ
    Vaccine; 2010 Mar; 28(15):2788-98. PubMed ID: 20139039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons.
    Andrejeva J; Young DF; Goodbourn S; Randall RE
    J Virol; 2002 Mar; 76(5):2159-67. PubMed ID: 11836393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
    Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
    Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.
    Schaap-Nutt A; Higgins C; Amaro-Carambot E; Nolan SM; D'Angelo C; Murphy BR; Collins PL; Schmidt AC
    J Virol; 2011 Apr; 85(8):4007-19. PubMed ID: 21289116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.
    Bartlett EJ; Cruz AM; Esker J; Castaño A; Schomacker H; Surman SR; Hennessey M; Boonyaratanakornkit J; Pickles RJ; Collins PL; Murphy BR; Schmidt AC
    J Virol; 2008 Sep; 82(18):8965-77. PubMed ID: 18614629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness.
    Nishio M; Ohtsuka J; Tsurudome M; Nosaka T; Kolakofsky D
    J Virol; 2008 Jul; 82(13):6130-8. PubMed ID: 18417591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children.
    Karron RA; Herbert K; Wanionek K; Schmidt AC; Schaap-Nutt A; Collins PL; Buchholz UJ
    J Pediatric Infect Dis Soc; 2023 Apr; 12(3):173-176. PubMed ID: 36594442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin-1 inhibits human parainfluenza virus type 2 dissemination.
    Yumine N; Matsumoto Y; Ohta K; Fukasawa M; Nishio M
    Virology; 2019 May; 531():93-99. PubMed ID: 30856486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain.
    Kawano M; Kaito M; Kozuka Y; Komada H; Noda N; Nanba K; Tsurudome M; Ito M; Nishio M; Ito Y
    Virology; 2001 May; 284(1):99-112. PubMed ID: 11352671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human parainfluenza virus type 2 V protein inhibits caspase-1.
    Ohta K; Matsumoto Y; Nishio M
    J Gen Virol; 2018 Apr; 99(4):501-511. PubMed ID: 29485395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced growth of influenza A virus by coinfection with human parainfluenza virus type 2.
    Goto H; Ihira H; Morishita K; Tsuchiya M; Ohta K; Yumine N; Tsurudome M; Nishio M
    Med Microbiol Immunol; 2016 Jun; 205(3):209-18. PubMed ID: 26582554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
    Nolan SM; Surman SR; Amaro-Carambot E; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(39):4765-74. PubMed ID: 15964103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response.
    Young DF; Didcock L; Goodbourn S; Randall RE
    Virology; 2000 Apr; 269(2):383-90. PubMed ID: 10753717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of amino acids essential for the human parainfluenza type 2 virus V protein to lower the intracellular levels of the STAT2.
    Kozuka Y; Yamashita Y; Kawano M; Tsurudome M; Ito M; Nishio M; Komada H; Ito Y
    Virology; 2003 Dec; 317(2):208-19. PubMed ID: 14698661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasally administered antigen 85B gene vaccine in non-replicating human Parainfluenza type 2 virus vector ameliorates mouse atopic dermatitis.
    Kitagawa H; Kawano M; Yamanaka K; Kakeda M; Tsuda K; Inada H; Yoneda M; Sakaguchi T; Nigi A; Nishimura K; Komada H; Tsurudome M; Yasutomi Y; Nosaka T; Mizutani H
    PLoS One; 2013; 8(7):e66614. PubMed ID: 23843958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paramyxovirus accessory proteins as interferon antagonists.
    Gotoh B; Komatsu T; Takeuchi K; Yokoo J
    Microbiol Immunol; 2001; 45(12):787-800. PubMed ID: 11838896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping.
    Nishio M; Tsurudome M; Garcin D; Komada H; Ito M; Le Mercier P; Nosaka T; Kolakofsky D
    J Virol; 2011 Jan; 85(2):725-32. PubMed ID: 21068245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.
    Fox CR; Parks GD
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.